McDermott and Bull executive Search
 

Other News

LivaNova to Present Autonomic Regulation Therapy Findings for Heart Failure During European Society of Cardiology Congress 2020

Coronary/Structural Heart by 0 comments

LONDON–(BUSINESS WIRE)–LivaNova PLC (NASDAQ:LIVN) a market-leading medical technology and innovation company, today announced it will present a poster at the European Society of Cardiology (ESC) Congress 2020 on the potential for autonomic regulation therapy (ART) via vagus nerve stimulation to improve long-term cardiovascular function in patients with heart failure. The virtual Congress […]

Continue Reading →

PhaseBio Reports Recent Business Highlights and Second-Quarter 2020 Financial Results

Financial by 0 comments

Received FDA authorization to proceed with “VANGARD” clinical trial to assess the efficacy and safety of PB1046 in hospitalized COVID-19 patients at high risk for rapid clinical deterioration and acute respiratory distress syndrome (ARDS) and commenced dosing of patients MALVERN, Pa. & SAN DIEGO–(BUSINESS WIRE)–PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage […]

Continue Reading →

BioVentrix Announces Appointment of Accredited Public Company Director Raymond W. Cohen to its Board of Directors

Financial by 0 comments

SAN RAMON, Calif.–(BUSINESS WIRE)–BioVentrix, Inc., a privately held medical device company focused on treating congestive heart failure via Transcatheter Ventricular Restoration (TCVR), today announced the appointment of Raymond W. Cohen to the Company’s board of directors. Mr. Cohen, an accredited public company director, has nearly 40 years of experience leading […]

Continue Reading →

Imricor Announces Sales Collaboration with Optoacoustics

Financial Radiology by 0 comments

MINNEAPOLIS–(BUSINESS WIRE)–Imricor Medical Systems, Inc. (Company or Imricor) (ASX:IMR), the global leader in MRI-guided cardiac ablation products, is pleased to announce a sales collaboration with Optoacoustics Ltd, the world leader in innovative, high performance optical communication solutions for magnetic resonance (MR) applications. The collaboration establishes a formal relationship between Imricor and Optoacoustics to facilitate […]

Continue Reading →

Shockwave Medical Reports Second Quarter 2020 Financial Results

Financial by 0 comments

SANTA CLARA, Calif., Aug. 11, 2020 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today reported financial results for the three months ended June 30, 2020. Recent Highlights Recognized revenue of $10.3 million […]

Continue Reading →

Neovasc Announces Closing of US$12.6 Million Registered Direct Offering Priced At-The-Market

Financial by 0 comments

Vancouver, Canada, Aug. 12, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ: NVCN / TSX: NVCN) announced today that it has closed its previously announced registered direct offering (the “Offering”) priced at-the-market under the Nasdaq rules of an aggregate of 4,532,772 common shares at a […]

Continue Reading →

FDA Accepts Evinacumab Biologics License Application for Priority Review as a Treatment for Patients with HoFH, an Ultra-rare Inherited Form of High Cholesterol

Coronary/Structural Heart Regulatory by 0 comments

TARRYTOWN, N.Y., Aug. 12, 2020 /PRNewswire/ — Homozygous familial hypercholesterolemia affects approximately 1,300 patients in the U.S., the vast majority of whom are unable to reach target LDL-C levels with currently available therapies Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review a […]

Continue Reading →

Medicure Reports Financial Results for Quarter Ended June 30, 2020

Financial by 0 comments

WINNIPEG, MB, Aug. 11, 2020 /PRNewswire/ – Medicure Inc. (“Medicure” or the “Company“) (TSXV: MPH) (OTC: MCUJF), a cardiovascular pharmaceutical company, today reported its results from operations for the quarter ended June 30, 2020. Quarter Ended June 30, 2020 Highlights: Net income for the quarter ended June 30, 2020 was $19,000 compared to net loss of $957,000 for the quarter ended June 30, […]

Continue Reading →

Milestone Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Clinical and Corporate Update

Financial by 0 comments

MONTREAL and CHARLOTTE, N.C., Aug. 12, 2020 /PRNewswire/ — Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the second quarter ended June 30, 2020 and provided a clinical and corporate update. “With the benefit of having completed our first Phase 3 clinical trial and […]

Continue Reading →
1 2 3 … 430